The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia
CNS drugs, 2015•Springer
Homomeric α 7 nicotinic acetylcholine receptors (α 7 nAChRs) have implications in the
regulation of cognitive processes such as memory and attention, and have shown promise
as a therapeutic target for the treatment of the cognitive deficits associated with
schizophrenia. Multiple α 7 nAChR agonists have entered human trials; however,
unfavorable side effects and pharmacokinetic issues have hindered the development of a
clinical α 7 nAChR agonist. Currently, EVP-6124 is in phase III clinical trials, and several …
regulation of cognitive processes such as memory and attention, and have shown promise
as a therapeutic target for the treatment of the cognitive deficits associated with
schizophrenia. Multiple α 7 nAChR agonists have entered human trials; however,
unfavorable side effects and pharmacokinetic issues have hindered the development of a
clinical α 7 nAChR agonist. Currently, EVP-6124 is in phase III clinical trials, and several …
Abstract
Homomeric α7 nicotinic acetylcholine receptors (α7 nAChRs) have implications in the regulation of cognitive processes such as memory and attention, and have shown promise as a therapeutic target for the treatment of the cognitive deficits associated with schizophrenia. Multiple α7 nAChR agonists have entered human trials; however, unfavorable side effects and pharmacokinetic issues have hindered the development of a clinical α7 nAChR agonist. Currently, EVP-6124 is in phase III clinical trials, and several other α7 nAChR agonists (GTS-21 and AQW051) are in earlier stages of development. This review will summarize the recent advances and failures of α7 nAChR agonists in clinical trials for the treatment of the aforementioned pathology.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果